<DOC>
	<DOC>NCT01980953</DOC>
	<brief_summary>This 4-part study will assess the effect of formulation, food, and active pharmaceutical ingredient (API) lot on the pharmacokinetics of GDC-0032 in healthy volunteers. Part 1 is an open-label, 3-period, 6-sequence study, and Parts 2, 3, and 4 are open-label 2-period crossover studies. Participants will receive single doses of GDC-0032 capsule or tablet formulation, in the fasted or fed state.</brief_summary>
	<brief_title>A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Males or females of nonchildbearing potential, between 18 and 55 years of age, inclusive; females will meet the following criteria: they will be nonpregnant, nonlactating, and either postmenopausal for at least 1 year or surgically sterile for at least 90 days. Body mass index (BMI) 18.5 to 32 kg/m^2, inclusive In good health, determined by no clinically significant findings from medical history, 12lead electrocardiogram (ECG), vital signs and clinical laboratory evaluations Negative test for selected drugs of abuse at Screening (does not include alcohol) and at each Checkin (Day 1; does include alcohol) Negative hepatitis panel (including hepatitis B surface antigen [HBsAg] and antihepatitis C virus [HCV]) and negative human immunodeficiency virus (HIV) antibody screens Males will either be sterile or agree to use approved methods of contraception as defined by protocol from Period 1 Checkin (Period 1, Day 1) until 90 days following the last dose of study drug Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the Investigator) History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs, except for appendectomy, hernia repair, and/or cholecystectomy History of alcoholism or drug addiction within 1 year prior to Period 1 Checkin (Period 1, Day 1) Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis History of Type 1 or 2 diabetes mellitus and/or elevated fasting glucose (greater than [&gt;] 120 milligrams per deciliter [mg/dL]) at baseline (as confirmed by repeat) History of Gilbert's Syndrome Evidence of malabsorption syndrome or other condition that would interfere with enteral absorption Inability or unwillingness to swallow pills or consume highfat breakfast Use of any tobacco or nicotinecontaining products within 6 months prior to Period 1 Checkin (Period 1, Day 1) and during the entire study Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 halflives or 30 days, whichever is longer, prior to Period 1 Checkin (Period 1, Day 1) and during the entire study duration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>